Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Esmya 5 mg Tablets (ulipristal acetate)

Active Ingredient:
ulipristal acetate
Company:  
Gedeon Richter (UK) Ltd See contact details
ATC code: 
G03XB02
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Letters to HCPs HCP Med Info
{arrow_left}
{arrow_right}

Important information for Healthcare Professionals

{pdf_link}

Esmya (UPA) 5mg - UK DHCP 29.01.2021

{healthcare_pro_orange} For Healthcare Professionals
This is a DHCP letter in agreement with the EMA and MHRA concerning new restrictions on the use of Esmya 5mg Tablets (ulipristal acetate) following conclusion of an Article 31 safety review.
{pdf_link}

Esmya (UPA) 5mg - UK DHPC 23.03.2020

{healthcare_pro_orange} For Healthcare Professionals
This is a DHPC letter as approved by EMA and MHRA following EMA’s Pharmacovigilance Risk Assessment Committee (PRAC)’s suggestion to suspend Esmya 5mg tablets (ulipristal acetate) during the ongoing Article 31 safety review.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Gedeon Richter (UK) Ltd
Company image
Address
127 Shirland Road, London, W9 2EP, UK
Medical Information Direct Line
+44 (0)207 604 8806
Medical Information Fax
Customer Care direct line
+44 (0)207 604 8800
WWW
http://www.gedeonrichter.co.uk
E-mail
[email protected]
Telephone
+44(0)207 604 8800
Medical Information e-mail
[email protected]